2019-nCoV Clinical Trial
Official title:
A Multicenter Observational Study About the Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children
The study is designed to clarify the clinical characteristics, risk factors and long-term prognosis of children with 2019-nCoV infection in China.
As of February 10th, 2020, more than 40,000 human have been confirmed infected with a novel
coronavirus (2019-nCoV) in China, with at least 800 reported deaths. Additional cases have
been confirmed in multiple countries, and some are reported in children. Patients with
confirmed 2019-nCoV infection have reported respiratory illness with fever, cough, et al.
Some are asymptomatic carriers. However, there are relatively few diagnosed cases of
children, and the long-term prognosis is unknown. Therefore, a multicenter observational
study is needed to better understand the clinical characteristics of 2019-nCoV infection in
children.
This observational study will last from February to December 2020. The patients enrolled were
diagnosed with 2019-nCoV infection or 2019-nCoV pneumonia by Beijing Children's Hospital and
other members of Chinese National Clinical Research Center for Respiratory Diseases in
2019-2020. At the same time, children hospitalized with pneumonia other than 2019-nCoV
pneumonia during the same period are classified as the control group by 3~5:1 matching for
age and sex to the 2019-nCoV group. After guardians signing the informed consent forms, all
the participants' clinical data, laboratory examination results, image data and also the
follow-up information after six months of their treatment will be collected.
The trial will be completed in 10 months, with subjects recruited from the hospitals that in
partnership with clinical research collaboration of National Clinical Research Center for
Respiratory Diseases.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT04334967 -
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
|
Phase 4 | |
| Not yet recruiting |
NCT04264858 -
Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients
|
N/A | |
| Withdrawn |
NCT04272710 -
Prognositc Factors in COVID-19 Patients Complicated With Hypertension
|
||
| Completed |
NCT04260594 -
Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus
|
Phase 4 | |
| Active, not recruiting |
NCT04273763 -
Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)
|
N/A | |
| Terminated |
NCT04261907 -
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection
|
N/A | |
| Not yet recruiting |
NCT04261426 -
The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04255017 -
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
|
Phase 4 | |
| Recruiting |
NCT04254874 -
A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia
|
Phase 4 | |
| Not yet recruiting |
NCT04356508 -
COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
|
Phase 2 | |
| Terminated |
NCT04321928 -
Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary
|
N/A |